- Sector: Health Technology
- Industry: Pharmaceuticals: Major
Revive Therapeutics Ltd. engages in the research, development, and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets. It offers the Relicann, a proprietary hemp-based cannabidiol chewing gum for the health and wellness. Its novel cannabinoid delivery technology targets diseases and disorders such as pain, inflammation, and wound care. The company was founded by Fabio Chianelli on March 27, 2012 and is headquartered in Vaughan, Canada.[bbp-topic-index] [bbp-topic-form]
Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
— Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical …
- Innocan’s SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union
- MJardin Group Announces Second Quarter 2020 Financial Results
- Green Thumb Industries and Cookies Enter Exclusive Partnership to Open Cookies on the Strip in Las Vegas
- Cronos Group Reports 2020 Second Quarter Results
- CannTrust Licenses Reinstated for Vaughan Manufacturing Facility
- Village Farms International to Host Second Quarter 2020 Conference Call on Thursday, August 13, 2020 at 8:30 a.m. ET
- Hollister Biosciences Inc. and Heavy Brands Inc. Enter into Letter of Intent for Proposed Joint Venture Agreement
- Acreage Announces Upcoming Conference Presentations
- Flower One Reports Strong Monthly Sales for the Month of July
- Nutritional High Announces Settlement of Payables and Update on Psychedelic Sciences Corp Acquisition.
All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. Candlr is not receiving payment or commissions from companies for shared content on Candlr website unless its specified. View full disclaimer HERE.